Chemotherapy can cause blood in your urine, and certain drugs are well-known for it. The condition most commonly linked to this problem is hemorrhagic cystitis, an inflammation of the bladder lining that ranges from microscopic traces of blood detectable only on a lab test to heavy, visible bleeding that requires emergency treatment. The drugs cyclophosphamide and ifosfamide are the most frequent culprits, though other mechanisms during cancer treatment can also send blood into your urine in ways that are easy to confuse with one another.
Why Certain Chemotherapy Drugs Damage the Bladder
The story with cyclophosphamide and ifosfamide starts not with the drugs themselves but with what your body turns them into. When your liver breaks down cyclophosphamide, it produces both the cancer-fighting compound and a toxic byproduct called acrolein. Acrolein has no therapeutic value. It’s waste, and your kidneys filter it into the urine, where it sits in direct contact with the bladder wall.1Australian and New Zealand Continence Journal. Acrolein, the toxic urinary metabolite of cyclophosphamide, causes physiological changes to bladder function
Once acrolein reaches the bladder’s inner lining, it enters the cells quickly and sets off a chain of damage. It triggers the production of highly reactive molecules inside the cells, which then attack cell membranes, proteins, and DNA. The DNA damage is severe enough to overwhelm the cell’s own repair systems, and the cells die. When enough of the bladder lining is destroyed this way, the raw, inflamed tissue underneath bleeds.2PubMed. Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation
The bladder is uniquely vulnerable because it serves as a holding tank. Unlike most organs, which are briefly exposed to a drug as it passes through the bloodstream, the bladder stores urine for hours. That prolonged contact time between acrolein and the bladder wall is what makes the damage so concentrated and so predictable with these drugs. Ifosfamide works through the same metabolic pathway and carries the same risk.
Other Chemotherapy Drugs That Affect the Urinary Tract
Cyclophosphamide and ifosfamide get the most attention because their bladder toxicity is direct and well understood, but they aren’t the only chemotherapy agents that can lead to blood in urine. Cisplatin, one of the most widely used cancer drugs, is notorious for kidney toxicity. Roughly a third of patients experience kidney injury within days of their first cisplatin treatment, and about one in five patients on high-dose regimens develop severe kidney dysfunction.3PubMed Central. Cisplatin-induced Kidney Dysfunction and Perspectives on Improving Treatment Strategies Kidney damage from cisplatin can show up as blood in the urine, though the source of that blood is the kidney itself rather than the bladder.
Doxorubicin and lomustine have also been linked to kidney and urinary tract complications, and cumulative dose plays a role. A study in pediatric oncology patients found that doxorubicin and ifosfamide had a statistically significant association with kidney-related side effects, with the total accumulated dose being an important factor.4Biomedicine & Pharmacotherapy. Chemotherapy induced kidney and urinary tract related complications: A study in the Department of Pediatric Oncology and Hematology The practical takeaway is that if you see blood in your urine during cancer treatment, your medical team will want to figure out whether it’s coming from the bladder, the kidneys, or somewhere else entirely, because the cause shapes the treatment.
Immune Checkpoint Inhibitors and a Different Kind of Bladder Inflammation
The newer class of cancer drugs called immune checkpoint inhibitors, which include PD-1 and PD-L1 antibodies, can cause blood in the urine through a completely different mechanism. These drugs work by unleashing the immune system against cancer cells, but sometimes the immune system also attacks healthy tissue. In rare cases, this includes the bladder and ureters.
Case reports describe patients on PD-1 antibody therapy developing cystitis and ureteritis with symptoms including urinary urgency, visible blood in the urine, and even kidney injury from swollen, blocked ureters. Unlike the chemical burn from acrolein, this is an immune-mediated inflammation. The good news is that these cases have responded well to steroid therapy, with urinary symptoms and kidney function returning to normal.5PubMed Central. Immune-related ureteritis and cystitis induced by immune checkpoint inhibitors: Case report and literature review These cases remain uncommon, but as checkpoint inhibitors are used more broadly, oncologists are increasingly alert to them.
Infections That Mimic Drug-Induced Bleeding
Cancer treatment suppresses the immune system, and a weakened immune system opens the door to infections that healthy people rarely have to worry about. Certain viruses, particularly BK virus, adenovirus, and cytomegalovirus, can cause hemorrhagic cystitis in patients who are immunocompromised, especially after stem cell or solid organ transplantation.6PubMed Central. Viral lower urinary tract infections
The symptoms of viral hemorrhagic cystitis look nearly identical to drug-induced cystitis: bloody urine, pain, frequent urination. But the treatment is very different. Drug-induced cystitis requires stopping or adjusting the offending medication, while viral cystitis requires antiviral therapy. This is one of the reasons your oncology team will run urine cultures and viral panels rather than assuming the chemotherapy is to blame when blood appears. Getting the diagnosis wrong can delay appropriate treatment in either direction.
Radiation Adds Another Layer of Risk
Many cancer patients receive both chemotherapy and radiation, and when radiation is directed at the pelvic area, the bladder takes a hit from both sides. Hemorrhagic cystitis is a recognized complication of pelvic radiotherapy on its own, and combining it with bladder-toxic chemotherapy raises the stakes.7Journal of Clinical Urology. Guidelines for the diagnosis, prevention and management of chemical- and radiation-induced cystitis
Radiation-induced bladder damage has a different timeline than chemotherapy damage. Chemotherapy-related hematuria often appears during or shortly after treatment cycles, while radiation cystitis can show up months or even years after radiation has ended. The radiation damages the small blood vessels in the bladder wall, and as those vessels become fragile over time, they can rupture and bleed. If you had pelvic radiation in the past and then start a bladder-toxic chemotherapy drug, you’re working with a bladder that’s already compromised, and your medical team should be factoring that history into their prevention plan.
How Doctors Prevent Hemorrhagic Cystitis
The most widely used prevention strategy is a drug called mesna (2-mercaptoethane sulfonate sodium). Mesna works by binding directly to acrolein in the urine, neutralizing it before it can damage the bladder lining. It’s typically given intravenously at the same time as cyclophosphamide or ifosfamide, and sometimes as additional oral doses afterward. A randomized trial comparing mesna against continuous bladder irrigation, which involves running saline through a catheter to physically flush the bladder, found both methods equally effective at preventing severe hemorrhagic cystitis in bone marrow transplant patients receiving high-dose cyclophosphamide.8PubMed. Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: a randomized trial
Aggressive hydration is the other cornerstone of prevention. The idea is simple: the more fluid passing through your system, the less time acrolein spends sitting in your bladder, and the more diluted it becomes. A separate randomized trial of 100 bone marrow transplant patients confirmed that mesna and vigorous intravenous hydration were equally effective at preventing cyclophosphamide-induced hemorrhagic cystitis.9PubMed. Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation In practice, many oncologists use both together, particularly for high-dose regimens, since the two strategies work through different mechanisms and the combination adds an extra margin of safety.
You’ll often be told to drink large volumes of water on the days you receive these drugs and to empty your bladder frequently, especially before bed. Letting urine sit in the bladder overnight, when you naturally go several hours without voiding, is exactly the scenario that gives acrolein the most contact time. Some centers will ask you to set an alarm and urinate every couple of hours through the night following treatment.
When Prevention Fails and Treatment Is Needed
Despite prevention efforts, some patients still develop hemorrhagic cystitis, and the severity varies enormously. Mild cases might involve just a pink tinge to the urine and some discomfort, which can resolve once the drug is stopped and the bladder lining regenerates. Severe cases involve heavy bleeding, clot formation that can block the urinary tract, and sometimes the need for surgical intervention.
For persistent or severe bleeding, doctors have a range of options. Bladder irrigation with various substances, including sodium hyaluronate, alum, and formalin, has been reported to help control hemorrhage. One approach using sodium hyaluronate showed that about 85% of patients had a partial or complete response, likely because the compound helps coat the damaged bladder lining and supports tissue healing.10Urological Science. Cyclophosphamide-induced intractable hemorrhagic cystitis treated with hyperbaric oxygenation and intravesical sodium hyaluronate
Hyperbaric oxygen therapy is another option that has been explored, particularly for radiation-induced hemorrhagic cystitis. The treatment involves breathing pure oxygen in a pressurized chamber, which promotes healing of damaged blood vessels and bladder tissue. Results have been mixed. In one series of ten patients treated for radiation-related bladder damage, six experienced total or partial resolution of their bleeding, but three saw no benefit, and one had to stop because the bleeding actually worsened.11PubMed Central. Hyperbaric oxygen therapy (HBOT) in case of hemorrhagic cystitis after radiotherapy That inconsistency reflects one of the frustrations of treating severe hemorrhagic cystitis: the condition remains genuinely difficult to manage, and no single treatment works reliably for everyone.
Timing and Cumulative Dose Matter
The risk of urinary tract complications from chemotherapy isn’t constant over the course of treatment. Research in pediatric oncology patients found that kidney-related complications tended to appear within the first two years after treatment, while urinary tract complications were more likely to surface over a longer window, up to five years after treatment ended.4Biomedicine & Pharmacotherapy. Chemotherapy induced kidney and urinary tract related complications: A study in the Department of Pediatric Oncology and Hematology That distinction matters because it means blood in your urine years after finishing chemotherapy could still be a late consequence of treatment rather than something unrelated.
Cumulative dose was also a significant factor. The more total drug exposure a patient had, the higher the risk of kidney and urinary tract side effects. This is one reason oncologists monitor kidney function closely throughout treatment and may adjust doses or switch drugs if early signs of damage appear. The type of cancer itself didn’t generally predict urinary complications, with one exception: sarcomas were associated with a higher rate, likely because the regimens used to treat them rely heavily on ifosfamide and doxorubicin.
What You Should Actually Do if You See Blood
If you’re receiving chemotherapy and notice blood in your urine, contact your oncology team promptly. Don’t wait for your next scheduled appointment, even if the amount seems small. A tiny amount of visible blood can represent significant bladder irritation, and catching hemorrhagic cystitis early, before it progresses to heavy bleeding and clot formation, makes it much easier to treat.
Be specific when you report it. Note the color (pink, red, or dark brown), whether you see clots, whether it hurts to urinate, and how often you’re going. These details help your team distinguish between bladder-origin bleeding, kidney-origin bleeding, and infection. Also mention if you’ve had any pelvic radiation in the past, since that changes the differential diagnosis.
It’s worth knowing that not all blood in the urine during cancer treatment means your chemotherapy is the cause. Urinary tract infections, both bacterial and viral, are common during chemotherapy because your immune defenses are lowered. Platelet counts can drop during treatment, making you more prone to bleeding from any surface in the body, including the urinary tract, without any specific organ damage. And sometimes a coincidental condition like a kidney stone or a pre-existing bladder issue is responsible. Your team will sort through these possibilities, but giving them good information up front speeds the process.
Microscopic Versus Visible Blood
There’s an important distinction between blood you can see and blood that only shows up on a urine test. Microscopic hematuria, where red blood cells are present in the urine but in quantities too small to change the color, is fairly common during chemotherapy and doesn’t always signal a serious problem. Your oncologist may monitor it without intervening, especially if it’s mild and your symptoms are manageable.
Gross hematuria, where the urine is visibly pink, red, or brownish, is a different matter. It signals heavier bleeding and usually triggers a more aggressive workup: imaging studies to look at the kidneys and bladder, cystoscopy to directly examine the bladder lining, and lab tests to check clotting function and rule out infection. The threshold for concern is lower during chemotherapy than it would be for someone not undergoing treatment, because the potential for rapid progression to severe hemorrhagic cystitis is real. Oncology teams would rather investigate and find nothing serious than miss a case that could have been caught early.
Long-Term Bladder Health After Chemotherapy
For most patients, mild hemorrhagic cystitis resolves once the offending drug is stopped and the bladder lining heals. But heavy or repeated episodes of bladder inflammation can leave lasting changes. Scar tissue may form in the bladder wall, reducing its capacity and flexibility. Some survivors report persistent urinary urgency and frequency long after treatment ends. In the most severe cases, the bladder can become fibrotic and contracted, sometimes requiring long-term management with medications that relax the bladder muscle or, very rarely, surgical reconstruction.
The five-year window for urinary tract complications highlighted in pediatric research applies to adults as well, and survivors of chemotherapy regimens that included cyclophosphamide, ifosfamide, or pelvic radiation should mention that treatment history to any new doctor, particularly urologists, who might otherwise look for more common explanations for their symptoms. A urologist who doesn’t know about your prior cyclophosphamide exposure might spend months investigating other causes of chronic bladder irritation before considering treatment-related damage, and that delay can affect the management approach.